We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+85.72%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$73.2M
Cap. Flow
-$340M
Cap. Flow %
-27.05%
Top 10 Hldgs %
36.58%
Holding
220
New
69
Increased
26
Reduced
46
Closed
56

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$13.6M
2
GOSS icon
Gossamer Bio
GOSS
+$8.85M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$7.61M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.3M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$6.53M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$23.1M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
3
IMVT icon
Immunovant
IMVT
+$12M
4
ARGX icon
argenx
ARGX
+$11.4M
5
VSTM icon
Verastem
VSTM
+$7.36M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
126
InflaRx
IFRX
$252M
$700K 0.06%
152,600
-110,000
-42% -$713K
DRNA
127
CALL
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$648K 0.05%
25,500
+10,000
+65% +$215K
PBYI icon
128
Puma Biotechnology
PBYI
$400M
$573K 0.05%
54,901
– –
IMMU
129
CALL
DELISTED
Immunomedics Inc
IMMU
$571K 0.05%
16,100
-100,000
-86% -$2.92M
MYOV
130
DELISTED
Myovant Sciences Ltd.
MYOV
$536K 0.04%
25,999
-424,001
-94% -$5.77M
SIOX
131
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$533K 0.04%
188,884
– –
OBSV
132
DELISTED
ObsEva SA Ordinary Shares
OBSV
$486K 0.04%
82,573
– –
GILD icon
133
Gilead Sciences
GILD
$162B
$478K 0.04%
+6,218
New +$477K
ADVM
134
DELISTED
Adverum Biotechnologies
ADVM
$477K 0.04%
+2,284
New +$405K
SRPT icon
135
CALL
Sarepta Therapeutics
SRPT
$1.6B
$417K 0.03%
2,600
-100,000
-97% -$13.6M
BXRX
136
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$415K 0.03%
71
-54
-43% -$259K
ARGX icon
137
argenx
ARGX
$53.6B
$394K 0.03%
1,750
-64,106
-97% -$11.4M
INCY icon
138
Incyte
INCY
$24.3B
$385K 0.03%
+3,700
New +$357K
GNFT
139
DELISTED
Genfit
GNFT
$353K 0.03%
+64,027
New +$750K
TVRD
140
CALL
Tvardi Therapeutics
TVRD
$19.5M
$335K 0.03%
544
– –
ARNA
141
DELISTED
Arena Pharmaceuticals Inc
ARNA
$315K 0.03%
+5,000
New +$275K
DRNA
142
PUT
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$254K 0.02%
+10,000
New +$215K
TPST icon
143
Tempest Therapeutics
TPST
$13.9M
$238K 0.02%
+693
New +$276K
SNDX icon
144
Syndax Pharmaceuticals
SNDX
$1.67B
$237K 0.02%
+16,000
New +$244K
BIIB icon
145
Biogen
BIIB
$30.3B
$213K 0.02%
795
– –
LEGN icon
146
Legend Biotech
LEGN
$3.57B
$213K 0.02%
+5,000
New +$195K
ITCI
147
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$185K 0.01%
7,202
-241,800
-97% -$4.89M
RARE icon
148
Ultragenyx Pharmaceutical
RARE
$2.45B
$181K 0.01%
2,313
-11,939
-84% -$790K
IWM icon
149
iShares Russell 2000 ETF
IWM
$80B
$165K 0.01%
1,154
-14,000
-92% -$1.84M
SRRA
150
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$118K 0.01%
+9,658
New +$120K
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Ikarian Capital held 220 positions worth $1.26B, down 5.5% from $1.33B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ikarian Capital withdrew a net $340M in Q2 2020, closing 56 positions and reducing 46 holdings. Its most notable exit was Acceleron Pharma, an estimated $23.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 20% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Blueprint Medicines worth $15.7M.

  • Ikarian Capital's largest Q2 2020 buy was Blueprint Medicines: 201,662 shares worth $15.7M.
  • Ikarian Capital added most to bluebird bio in Q2 2020, an estimated $5.73M increase.
  • Ikarian Capital's biggest Q2 2020 reduction was BioXcel Therapeutics, cutting an estimated $17.3M.
  • Ikarian Capital fully exited Acceleron Pharma in Q2 2020, selling an estimated $23.1M.
  • Ikarian Capital's ten largest holdings make up 37% of its $1.26B portfolio in Q2 2020.
  • Ikarian Capital opened 69 new positions and closed 56 in Q2 2020.
  • Ikarian Capital's portfolio value fell 5.5% quarter-over-quarter to $1.26B.

Based on Ikarian Capital's 13F filing for Q2 2020, filed 14 Aug 2020.